American Society of Hematology

Figure 4.

$Figure 4. HSCs labeled by Fgd5-CreER contribute to steady-state hematopoiesis. (A) Experimental setup. Fgd5-CreER; tdTomato mice (3-6 months old) were injected with tamoxifen for 5 days and analyzed at 1, 4, and 26 weeks after the first injection. (B-D) Longitudinal analysis of tdTomato+ fraction in the indicated populations at 1 (B), 4 (C), and 26 (D) weeks after tamoxifen treatment (n = 3-9). (E) Experimental setup to examine the effect of 5-FU treatment on Fgd5-CreER–based labeling. Fgd5-CreER; tdTomato mice were injected with tamoxifen for 5 days, then with 5-FU at 2 weeks after the first tamoxifen injection. Peripheral blood (PB) was analyzed at weeks 3 and 4 (n = 3-4). (F) Peripheral blood analysis for tdTomato+ cells in the indicated population revealed increased tdTomato+ cells after 5-FU treatment. All data represent mean ± SEM. In panels B-D, ***P < .001 (1-way ANOVA with post hoc Tukey’s multiple comparison test against all other groups) and ##P < .01 (1-way ANOVA with post hoc Tukey’s multiple comparison test against all other groups except for HSC and HPC2). In panel F, *P < .05 and ***P < .001 (Student t test). PLT, platelet.$

HSCs labeled by Fgd5-CreER contribute to steady-state hematopoiesis. (A) Experimental setup. Fgd5-CreER; tdTomato mice (3-6 months old) were injected with tamoxifen for 5 days and analyzed at 1, 4, and 26 weeks after the first injection. (B-D) Longitudinal analysis of tdTomato⁺ fraction in the indicated populations at 1 (B), 4 (C), and 26 (D) weeks after tamoxifen treatment (n = 3-9). (E) Experimental setup to examine the effect of 5-FU treatment on Fgd5-CreER–based labeling. Fgd5-CreER; tdTomato mice were injected with tamoxifen for 5 days, then with 5-FU at 2 weeks after the first tamoxifen injection. Peripheral blood (PB) was analyzed at weeks 3 and 4 (n = 3-4). (F) Peripheral blood analysis for tdTomato⁺ cells in the indicated population revealed increased tdTomato⁺ cells after 5-FU treatment. All data represent mean ± SEM. In panels B-D, ***P < .001 (1-way ANOVA with post hoc Tukey’s multiple comparison test against all other groups) and ##P < .01 (1-way ANOVA with post hoc Tukey’s multiple comparison test against all other groups except for HSC and HPC2). In panel F, *P < .05 and ***P < .001 (Student t test). PLT, platelet.

This Feature Is Available To Subscribers Only